United States Patent 5,578,578: Claim Scope, Expiration, and Ophthalmic Patent Landscape

U.S. Patent 5,578,578 claims ophthalmic solutions containing a viscous or viscoelastic material, such as hydroxypropylmethylcellulose, in a physiologically compatible salt solution that includes bicarbonate ions. The independent claim is composition-based and requires both the rheology-modifying material and bicarbonate-containing salt medium. The patent’s principal commercial relevance was protection for buffered, lubricating or viscoelastic ophthalmic formulations rather than protection for a specific active pharmaceutical ingredient.

The patent issued in 1996. Under the modern 20-year patent-term rule, its enforceable term would ordinarily have ended no later than the early-to-mid 2010s, subject to the patent’s earliest effective nonprovisional filing date, patent-term adjustment, terminal disclaimers, and any applicable extension. The claims should therefore be treated as expired for present U.S. freedom-to-operate analysis unless the USPTO record establishes an unusual term adjustment or extension.[1][2]

What does U.S. Patent 5,578,578 claim?

Claim 1: broad ophthalmic composition claim

Claim 1 requires all of the following elements:

Claim element	Scope
Ophthalmic solution	A liquid preparation intended for ophthalmic administration
Therapeutically effective amount	A sufficient amount of the selected viscous or viscoelastic material to produce the claimed therapeutic function
Viscous or viscoelastic material	Collagen, modified collagen, modified cellulose, or combinations
Physiologically compatible salt solution	A salt-containing aqueous medium compatible with ocular administration
Bicarbonate ions	Bicarbonate must be present in the salt solution

The claim is not limited to a particular disease, active drug, pH, osmolarity, viscosity, container, preservative system, or dosing schedule. It is also not expressly limited to contact-lens solutions, artificial tears, surgical irrigation fluids, or a specific therapeutic indication.

The claim’s breadth is controlled by the combination of material and buffer limitations. A formulation containing hydroxypropylmethylcellulose but no bicarbonate would not satisfy claim 1 literally. Conversely, a bicarbonate-buffered ophthalmic solution without collagen, modified collagen, modified cellulose, or a qualifying combination would also fall outside the literal claim.

What materials fall within claim 1?

The Markush group covers:

Collagen;
Modified collagen;
Modified cellulose; and
Combinations of those materials.

Hydroxypropylmethylcellulose, commonly abbreviated HPMC or hypromellose, is expressly identified in claim 3 as one covered modified cellulose. Other cellulose derivatives could potentially fall within claim 1 if they meet the claim’s “modified cellulose” limitation and function as a viscous or viscoelastic material.

The claim does not define the required molecular weight, degree of substitution, viscosity grade, concentration, or source of the cellulose derivative. Those parameters would likely become relevant in claim construction, infringement analysis, and validity proceedings.

How do the dependent claims narrow the patent?

Claim 2: balanced electrolyte formulation

Claim 2 requires the solution of claim 1 to contain sodium, potassium, calcium, and magnesium ions in addition to bicarbonate.

This limitation points to a physiologically balanced salt formulation. The claim does not state the concentration of each cation. A formulation with trace quantities could raise a claim-construction issue, but the ions would still need to be present in a meaningful and technically supportable form.

Claim 2 is narrower than claim 1 because it requires all four specified cations. A product containing sodium and potassium but no calcium or magnesium would not literally satisfy claim 2, although it could still satisfy claim 1 if the other elements are present.

Claim 3: hydroxypropylmethylcellulose formulation

Claim 3 narrows claim 1 by specifying HPMC as the viscous or viscoelastic material.

The claim still requires bicarbonate-containing physiologically compatible salt solution. HPMC alone is insufficient. An HPMC ophthalmic formulation buffered only with phosphate, borate, citrate, acetate, or another non-bicarbonate system would not meet the express bicarbonate limitation.

Claim 4: bicarbonate concentration

Claim 4 requires bicarbonate ions at a concentration of approximately 10 mM/L to approximately 50 mM/L.

The range is the only express quantitative limitation in the four claims. The use of “about” creates tolerance around the endpoints. The scope would ordinarily be assessed using the specification, prosecution history, analytical measurement method, and ordinary technical meaning of the concentration term.

A formulation containing 10-50 mM bicarbonate is the clearest literal target. Concentrations marginally below 10 mM/L or above 50 mM/L would require analysis of the meaning of “about” and, potentially, the doctrine of equivalents.

What formulation combinations are protected?

The claim set covers several formulation categories:

Formulation category	Claim exposure
Collagen plus bicarbonate-containing salt solution	Claim 1
Modified collagen plus bicarbonate-containing salt solution	Claim 1
HPMC plus bicarbonate-containing salt solution	Claims 1 and 3
Other qualifying modified cellulose plus bicarbonate-containing salt solution	Claim 1
Any covered material plus sodium, potassium, calcium, magnesium and bicarbonate	Claim 2
Any claim 1 formulation with 10-50 mM/L bicarbonate	Claim 4

The claims do not require all four cations unless claim 2 is asserted. They do not require the 10-50 mM/L range unless claim 4 is asserted. They do require bicarbonate for every claim because claims 2-4 depend directly or indirectly on claim 1.

What is the likely infringement test?

A U.S. composition claim is infringed when a product contains every limitation of the asserted claim, either literally or under the doctrine of equivalents, subject to prosecution-history estoppel and other limits under patent law.[3]

For claim 1, the principal technical questions would be:

Is the product an ophthalmic solution?
Does it contain a qualifying collagen or modified cellulose material?
Is that material present in a therapeutically effective amount?
Is the carrier a physiologically compatible salt solution?
Does the solution contain bicarbonate ions?

For claim 3, the formulation would need HPMC specifically. For claim 4, the bicarbonate concentration would need to fall within the interpreted “about 10 mM/L to about 50 mM/L” range.

A product that uses a different viscosity agent, such as polyvinyl alcohol, carbomer, polyethylene glycol, or hyaluronic acid, may avoid literal infringement if the agent is not a qualifying modified cellulose or collagen material. The doctrine of equivalents could still become relevant, but equivalence cannot erase a claim limitation or capture subject matter surrendered during prosecution.

When did U.S. Patent 5,578,578 lose exclusivity?

Patent-term analysis

Patent No. 5,578,578 issued on November 26, 1996. Patent term depends on the effective filing date and applicable statutory rules. For patents subject to the Uruguay Round Agreements Act term provisions, the ordinary term is 20 years from the earliest effective nonprovisional U.S. filing date, rather than 17 years from issuance.[1]

The practical conclusion is:

Issue	Assessment
Issue date	November 26, 1996
Ordinary term basis	20 years from earliest effective nonprovisional filing
Likely commercial status today	Expired
Potential term modifiers	Patent-term adjustment, terminal disclaimer, reexamination adjustment, or regulatory extension
Current blocking value	Generally none if the patent is expired

A precise expiration date requires the USPTO patent record showing the earliest effective filing date and any patent-term adjustment or disclaimer. The issued claims themselves do not establish that date.

An expired patent can remain relevant as prior art, prosecution-history evidence, or a record of technical disclosure, but it ordinarily cannot support a new U.S. infringement claim for activities occurring after expiration.

What is the Orange Book status of U.S. Patent 5,578,578?

The Orange Book lists patents submitted by NDA holders for approved drug products when the patents meet FDA listing requirements. A formulation patent is not automatically an Orange Book patent merely because it covers an ophthalmic solution.[4]

The patent’s Orange Book relevance depends on whether:

An approved NDA holder submitted it for a specific drug product;
FDA accepted the listing;
The listed patent covered the drug substance, drug product, or approved method of use; and
The listing remained relevant during the patent’s life.

Because the claims are directed to a formulation platform rather than a clearly identified active ingredient, Orange Book listing would depend heavily on the approved product and the NDA holder’s submission. If the patent was listed, its expiration would eliminate any continuing patent-based barrier after the term ended.

Paragraph IV implications

A Paragraph IV certification applies when an ANDA applicant asserts that a listed patent is invalid, unenforceable, or will not be infringed. A patent that has already expired generally does not create a continuing Paragraph IV launch barrier.[5]

The patent could have supported a Paragraph IV dispute during its term if it was listed against an approved ophthalmic product and the ANDA product contained the claimed formulation. That historical possibility does not establish a current regulatory obstacle.

Does the patent cover an active pharmaceutical ingredient?

No active pharmaceutical ingredient is recited in the supplied claims.

The claims cover the formulation vehicle and rheology-modifying component. They may therefore read on:

Lubricating ophthalmic solutions;
Artificial tear formulations;
Ophthalmic solutions containing an active drug;
Surgical or perioperative ophthalmic fluids; and
Other ocular solutions containing a covered polymer or collagen material.

Whether an active drug is present does not remove the formulation from claim scope. A product containing both an active ingredient and the claimed excipient system could satisfy the claims if every limitation is met.

The claims do not protect the active ingredient itself, its synthesis, a specific salt form, a crystalline form, or a disease-specific method of treatment.

What manufacturing and formulation barriers does the patent create?

The technical barrier is relatively focused. A competing product would need to design around one or more of the following:

Design-around path	Potential effect
Remove bicarbonate	Avoids a central limitation of all four claims
Use a non-cellulose, non-collagen viscosity agent	May avoid the material limitation
Use a non-viscous formulation	May avoid the claimed material limitation
Use a different buffer system	May avoid bicarbonate limitation
Use bicarbonate outside the claim 4 range	May avoid claim 4, but not claim 1
Omit one or more cations	Avoids claim 2, but not necessarily claim 1
Use a non-ophthalmic dosage form	Avoids the ophthalmic-solution limitation

The strongest design-around strategy is usually removal of bicarbonate or replacement of the covered viscosity modifier. Changing only the cation profile does not avoid claim 1. Changing bicarbonate concentration outside the claim 4 range does not avoid claims 1-3.

Because the patent is expired, these design-around options are primarily relevant to historical analysis, patent-family review, or later patents that may have used similar technical concepts.

How strong is the patent estate?

The supplied claim set indicates a narrow patent estate centered on one formulation concept. It has several weaknesses from a present commercial perspective:

The patent term has likely expired;
The claims do not protect an active ingredient;
The claims do not recite a specific commercial product;
The claims contain multiple structural limitations;
The formulation must include bicarbonate;
The principal independent claim lacks a numerical concentration limit for the viscosity modifier, which may create breadth but also support enablement and written-description challenges depending on the specification.

The estate’s historical strength would have depended on the specification’s examples, the definition of “modified cellulose,” the disclosure of bicarbonate concentrations, and prosecution amendments. The independent claim is broader than claims 2-4, but it remains constrained by the requirement for a qualifying viscoelastic material and bicarbonate-containing salt solution.

Which companies challenged the patent, and what litigation affected it?

No litigation, Paragraph IV challenge, settlement agreement, or licensing transaction can be established from the claim text alone. Patent litigation records must be tied to the patent number, its owner, asserted claims, named defendants, and docket history.

The relevant historical litigation questions are:

Whether an NDA holder listed the patent in the Orange Book;
Whether an ANDA applicant filed a Paragraph IV certification;
Whether the patent owner brought an infringement action before expiration;
Whether any case produced a claim-construction ruling;
Whether the parties entered a launch-date settlement; and
Whether a reexamination, disclaimer, or terminal disclaimer affected enforceability.

Absent a live patent term, the patent does not present a current U.S. launch-blocking risk on its own.

How does this patent compare with later ophthalmic formulation patents?

Patent 5,578,578 is an early formulation patent with broad genus language covering collagen and modified cellulose materials in bicarbonate-containing salt solutions. Later ophthalmic patents commonly pursue narrower protection in one or more of these areas:

A specific active ingredient;
A defined polymer concentration;
A preservative-free multidose container;
A particular pH or osmolality;
A specified viscosity range;
Improved residence time or comfort;
A combination therapy;
A specific dosing regimen;
A manufacturing or sterilization process; or
A device-plus-formulation combination.

Such later patents may remain relevant even though Patent 5,578,578 has expired. The earlier patent could operate as prior art against later claims, but it does not automatically invalidate every later patent. Novelty and obviousness depend on the precise disclosure and claim limitations of each later filing.[6]

Is there biosimilar risk?

Biosimilar risk is not the appropriate framework for this patent. The claims cover an ophthalmic solution and excipient system, not a biologic drug substance. A competing product would normally proceed through an abbreviated new drug application, a 505(b)(2) application, or another applicable FDA pathway rather than the biosimilar pathway under the Public Health Service Act.[7]

A collagen-containing ophthalmic product could raise separate regulatory questions if the collagen were biologically derived, structurally complex, or used as an active biological component. The supplied claims do not establish that the product is a biologic.

Key Takeaways

Claim 1 covers ophthalmic solutions containing collagen, modified collagen, modified cellulose, or combinations in a bicarbonate-containing physiologically compatible salt solution.
Claim 2 adds sodium, potassium, calcium, and magnesium ions.
Claim 3 specifically covers HPMC formulations.
Claim 4 covers bicarbonate concentrations of approximately 10-50 mM/L.
The claims protect formulation architecture, not an active pharmaceutical ingredient.
A product without bicarbonate is outside the literal scope of all four supplied claims.
A product using a non-cellulose, non-collagen viscosity agent may provide a strong design-around position.
The patent issued in 1996 and is likely expired under the applicable 20-year patent-term framework.
Current Paragraph IV, Orange Book, litigation, and licensing significance cannot be inferred from the claim language alone.
Biosimilar analysis is generally not applicable because the claims cover an ophthalmic formulation rather than a biologic drug substance.

FAQs

Does an HPMC artificial tear infringe Patent 5,578,578?

Only if it also satisfies the ophthalmic-solution, therapeutically effective amount, physiologically compatible salt solution, and bicarbonate-ion limitations. HPMC alone is insufficient.

Does a phosphate-buffered HPMC eye drop fall within the claims?

Not literally if it contains no bicarbonate ions. Claim 1 and all dependent claims require bicarbonate.

Does claim 4 require sodium, potassium, calcium, and magnesium?

No. Claim 4 depends directly on claim 1 and adds the bicarbonate concentration range. The four-cation requirement appears in claim 2.

Can an expired patent still affect an ophthalmic generic launch?

It cannot ordinarily block post-expiration commercialization, but it may remain relevant as prior art, prosecution-history evidence, or background to later patent disputes.

Is a bicarbonate concentration of 5 mM/L covered?

It may fall outside claim 4, but it could still satisfy claim 1 if the product contains the other required elements. The word “about” makes endpoint analysis dependent on the patent record and technical context.

References

United States Code. (2024). 35 U.S.C. § 154: Contents and term of patent; provisional rights. https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title35-section154
United States Patent and Trademark Office. (n.d.). Patent term adjustment and patent term information. https://www.uspto.gov/patents/laws/patent-term-calculator
United States Code. (2024). 35 U.S.C. §§ 271, 273: Infringement of patent and defenses. https://uscode.house.gov/view.xhtml?path=/prelim@title35/partIII/chapter28
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
U.S. Food and Drug Administration. (2024). 21 C.F.R. § 314.101: Filing an NDA and an ANDA. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-314
United States Code. (2024). 35 U.S.C. §§ 102-103: Conditions for patentability and non-obvious subject matter. https://uscode.house.gov/view.xhtml?path=/prelim@title35/partII/chapter10
U.S. Food and Drug Administration. (2024). Biosimilar and interchangeable biosimilar products. https://www.fda.gov/drugs/biosimilars/biosimilar-and-interchangeable-biosimilar-products

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2389595	⤷ Start Trial
World Intellectual Property Organization (WIPO)	9632929	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 5,578,578

Summary for Patent: 5,578,578